The power and speed of genetic engineering

Novavax addresses urgent global public health needs with innovative technology

Recombinant Nanoparticle Vaccine Technology

Our recombinant nanoparticle vaccine technology combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles that target a variety of viral pathogens. Our recombinant vaccine engineering takes a new approach to provide robust and functional immunity, which may be more efficacious than naturally occurring immunity or traditional vaccines. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats.

How we create our
nanoparticles

Recombinant Nanoparticle Advantages

Promote superior immunogenicity and better functional immunity via our Sf9/BV insect cell platform to efficiently express large antigens and particles.

Recombinant Nanoparticle Advantages

Ability to leverage our proprietary vaccine technology, which produces highly immunogenic vaccines in a scalable, efficient recombinant vaccine production system.

Select genetic sequences to encode vaccine antigens

Genes are cloned into baculovirus (BV)

BV infects Sf9 insect cells

Antigens are expressed and purified as multimeric nanoparticles

Immunogenic particle with antigens in native configuration are created

Recombinant Nanoparticle Advantages

Ability to tailor our vaccines to key components of pathogens to enhance functional immunity and lead to better protection against infection and disease.

Recombinant Nanoparticle Advantages

Ability to manufacture and produce proteins that are properly folded and modified, which can be critical for functional, protective immunity.

Recombinant Nanoparticle Advantages

Ability to tailor our vaccines to key components of pathogens to enhance functional immunity and lead to better protection against infection and disease.

Promote superior immunogenicity and better functional immunity via our Sf9/BV insect cell platform to efficiently express large antigens and particles.

Ability to manufacture and produce proteins that are properly folded and modified, which can be critical for functional, protective immunity.

Ability to leverage our proprietary vaccine technology, which produces highly immunogenic vaccines in a scalable, efficient recombinant vaccine production system.

Novavax’ recombinant protein
nanoparticle vaccine technology

Powered by an innovative formulation

Matrix-M™ adjuvant technology stimulates strong responses

Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing.

Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.

Matrix-M™ adjuvant

Matrix-M is composed of 40 nanometer particles based on saponin extracted from the Quillaja saponaria Molina bark together with cholesterol and phospholipid.

Matrix-M can lower the dose of antigen required to achieve the desired immune response, which results in fewer vaccine doses needed and increased supply and manufacturing capacity.

Induces the influx of antigen-presenting cells (APC), which enhance activated T cell, B cell, and APC populations.

Increases neutralizing antibodies and induces long-lasting memory B cells, which enhance B-cell immunity and recruit and increase the frequency of CD4+ and CD8+ T cells that enhance T-cell immunity.

Matrix-M provides strong and long-lasting immune responses, which can enable dose-sparing.

Matrix-M enhanced biologic functions to generate potent, robust, and long-lasting protective immune responses.

Matrix-M is composed of 40 nanometer particles based on saponin extracted from the Quillaja saponaria Molina bark together with cholesterol and phospholipid.

Matrix-M enhanced biologic functions to generate potent, robust, and long-lasting protective immune responses.

Matrix-M can lower the dose of antigen required to achieve the desired immune response, which results in fewer vaccine doses needed and increased supply and manufacturing capacity.